Idioma:

Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients

Eggemann, Holm ; Ignatov, Atanas ; Smith, Bobbie J. ; Altmann, Udo ; von Minckwitz, Gunter ; Röhl, Freidrich W. ; Jahn, Mark ; Costa, Serban-Dan

Breast cancer research and treatment, 2013-01, Vol.137 (2), p.465-470 [Periódico revisado por pares]

Boston: Springer US

Texto completo disponível

Citações Citado por

Enviar para

Título:
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
Autor: Eggemann, Holm ; Ignatov, Atanas ; Smith, Bobbie J. ; Altmann, Udo ; von Minckwitz, Gunter ; Röhl, Freidrich W. ; Jahn, Mark ; Costa, Serban-Dan
Assuntos: Adjuvant treatment ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Hormonal - therapeutic use ; Aromatase Inhibitors - therapeutic use ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms, Male - drug therapy ; Breast Neoplasms, Male - metabolism ; Breast Neoplasms, Male - mortality ; Breast Neoplasms, Male - pathology ; Cancer ; Cancer patients ; Cancer research ; Cancer therapies ; Care and treatment ; Chemotherapy, Adjuvant ; Clinical Trial ; Comparative studies ; Drug therapy ; Follow-Up Studies ; Germany ; Gynecology. Andrology. Obstetrics ; Humans ; Male ; Males ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Mortality ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Oncology ; Receptors, Estrogen - metabolism ; Tamoxifen ; Tamoxifen - therapeutic use ; Toy industry ; Treatment Outcome ; Tumors
É parte de: Breast cancer research and treatment, 2013-01, Vol.137 (2), p.465-470
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Descrição: To determine the impact of adjuvant treatment with tamoxifen and aromatase inhibitors (AI) on the survival of men with breast cancer. We analyzed 257 male patients with hormone-receptor-positive breast cancer from numerous German population-based cancer registries treated with tamoxifen ( N = 207) or aromatase inhibitors ( N = 50). The median follow-up was 42.2 (range 2–115) months. Median age at diagnosis was 68 (range 36–91) years. Thirty-seven (17.9 %) patients treated with tamoxifen and 16 (32.0 %) patients treated with AI died (log rank p = 0.007). After the adjustment for the patient’s age, tumor size, node status, and tumor grading, the AI treatment was linked to a 1.5-fold increase in risk of mortality compared to tamoxifen (HR 1.55; 95 % CI: 1.13–2.13; p = 0.007). The overall survival in male breast cancer was significantly better after adjuvant treatment with tamoxifen compared to an aromatase inhibitor. Tamoxifen should be considered as the treatment of choice for hormone-receptor-positive male breast cancer.
Editor: Boston: Springer US
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients

Eggemann, Holm ; Ignatov, Atanas ; Smith, Bobbie J. ; Altmann, Udo ; von Minckwitz, Gunter ; Röhl, Freidrich W. ; Jahn, Mark ; Costa, Serban-Dan

Boston: Springer US

Buscando em bases de dados remotas. Favor aguardar.